I really don't know how Gerald will choose to monetize Lympro. He said just a couple weeks ago that they had several options and various discussions were on going.

Gerald's comment that "Someone might pay x now, but 100x down the road," seems to apply here. It makes sense to me that Lympro will be much more valuable after it has proven to pharma that it is accurate, less expensive, and easier to use than Amivid.

I am merely speculating. Cash needs to come from somewhere in Q1, but I don't have the faintest where Gerald will get it from.